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Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is 
responsible for the second highest cancer-related male mortality rate in Western coun-
tries, with increasing rates being reported in Korea, Japan, and China. Considering 
the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that 
reliable, age-independent markers of the presence, nature, and progression of PCa are 
required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics 
has recently emerged as a novel method of PCa detection owing to its ability to monitor 
changes in the metabolic signature, within biofluids or tissue, that reflect changes in 
phenotype and function. This review outlines the physiology of prostate tissue and pro-
static fluid in health and in malignancy in relation to metabolomics as well as the princi-
ples underlying the methods of metabolomic quantification. Promising metabolites, 
metabolic profiles, and their correlation with the presence and stage of PCa are 
summarized. Application of metabolomics to biofluids and in vivo quantification as well 
as the direction of current research in supplementing and improving current methods 
of detection are discussed. The current debate in the urology literature on sarcosine 
as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises 
to be a valuable tool in the early detection of PCa that may enable earlier treatment 
and improved clinical outcomes.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed vis-
ceral cancer in men and is responsible for the second high-
est cancer-related male mortality rate in Western coun-
tries, with increasing rates being reported in Korea, Japan, 
and China [1-4]. Such high rates of mortality are attributed 
to the nature of the disease and its range in distribution and 
varied levels of aggressive behavior [5]. Current treatment 
focuses on early detection of PCa to enable early inter-
vention which in turn enhances the likelihood of treatment 
success [6]. 
Currently, serum prostate-specific antigen (PSA) re-
mains the standard initial test for PCa detection, although 
controversy surrounds its limited sensitivity and specific-
ity [7-12]. Moreover, PSA does not provide prognostic in-
formation [10,13]. The strong positive association of PSA 
with age [14] and other prostatic conditions, including be-
nign prostatic hyperplasia (BPH) [15,16], inevitably leads 
to many false-positive results. False-negative results are 
also common, as no reliable cutoff value exists for PSA to 
rule out the presence of PCa [9]. In addition, the current 
method of definitive diagnosis, biopsy, misses many tu-
mors [17]. In this context, it is widely agreed that reliable, 
age-independent markers of the presence of PCa, its na-
ture, and its progression beyond the prostate are required 
to enable individual treatment to occur in a timely manner 
[18-21]. Metabolomics has recently emerged as a promis-Korean J Urol 2011;52:79-89
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FIG. 1. Summary of targets in the 
‘omic’ era of analysis. The hierarchical
levels of cellular organization in-
volved in the progression from geno-
type to phenotype are shown. This 
expression of cellular phenotype is 
tightly regulated by feedback mecha-
nisms, as shown above the progres-
sion. Through this process, various 
targets are available for analysis and 
opportunistic manipulation, as shown 
below the progression.
ing method of PCa detection [22], one that may supplement, 
or even eventually replace, current PSA testing in provid-
ing diagnostic accuracy. 
The objective of this article was to review the current sta-
tus of metabolomics in facilitating the early diagnosis of 
PCa, in addition to other benefits it may provide for clini-
cians in the future. 
METABOLOMICS AND THE PROSTATE
Metabolomics can detect and quantify low-molecular- 
weight metabolites produced by living cells [5]. Metabolo-
mics has been described as “the quantitative measurement 
of the dynamic multiparametric metabolic response of liv-
ing systems to pathophysiological stimuli or genetic mod-
ification” [23]. The metabolites of living cells are seen as 
the end products of the biological hierarchy starting with 
activated genes (genome) and extending over the collection 
of gene transcripts (transcriptome) and proteins (proteome). 
This process is summarized in Fig. 1. 
Neoplastic transformation is considered to necessitate 
metabolic alterations to provide the bioenergetic and syn-
thetic requirements of malignancy [24]. It is on this basis 
that alterations to the metabolic signatures within bio-
fluids or tissues reflect changes in phenotype and function 
and are key to differentiating tumors from normal tissues 
[25-27]. Moreover, it is believed that metabolic alterations 
precede neoplastic proliferation. Thus, if such precancer-
ous metabolic alterations are detectable, early inter-
vention may even prevent cancer development or minimize 
neoplastic proliferation and invasion of local or distant 
structures. Metabolomics has enormous potential as a 
less-invasive screening agent via chemical analysis of bio-
fluids and other biological samples, such as biopsies or tis-
sue samples, or through molecular imaging techniques 
such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET) [28]. 
PROSTATE PHYSIOLOGY IN HEALTH AND 
DISEASE
In the prostate, the peripheral zone (PZ) constitutes not on-
ly the majority of the volume (70%) and function, but also 
the majority of malignancy rates (85%) [29]. The function 
of the PZ epithelium is the production, storage, and secre-
tion of prostatic fluid, which is composed of citrate, poly-
amines (spermine, myoinositol), and PSA [30-32]. The cit-
rate concentration in the PZ is 20-70 times that in blood 
plasma, whereas citrate levels in prostatic fluid are 400- 
1,500 higher than in blood plasma [29]. Production of these 
metabolites makes the PZ epithelium unique among hu-
man cells, because intracellular metabolism significantly 
favors citrate synthesis over citrate utilization. Normally 
in cells, citrate is reversibly isomerized to isocitrate as part 
of the Krebs cycle by the enzyme m-aconitase. However, the 
presence of extraordinarily high levels of zinc in prostate 
cells inhibits m-aconitase activity and allows for metabol-
ically efficient citrate complexation in the PZ, which is later 
secreted as prostatic fluid. Because the Krebs cycle is not 
completed, typical ATP production is impaired, and the de-
mand on glucose and aspartate by PZ cells is increased [29]. 
This process is summarized on the left side of Fig. 2.
In general, malignant transformation impairs normal 
mitochondrial functioning, requiring elevated glycolysis 
and lactic acid fermentation in the cytosol and production 
of lactate and alanine. This increases the glucose require-
ment and uptake in malignant cells and is known as the 
Warburg effect [33]. In contrast, and unique to PCa, is the 
inability of PZ epithelial cells to accumulate zinc. The re-
sulting low zinc concentration allows m-aconitase to be ac-
tive, citrate to be isomerized, and the previously truncated 
Krebs cycle to be completed, resulting in the production of 
an extra 24 ATP molecules through complete glucose oxida-
tion and oxidative phosphorylation. Consequently, the in-
creased level of oxidative phosphorylation produces more 
free radicals due to increased flux in the electron transport 
chain and accelerates neoplastic transformation [34]. In 
short, metabolism in malignant PCa cells is more efficient 
in producing bioenergy than is that in normal PZ epithelial 
cells, which is the opposite of most other malignant 
processes. This requires that further treatment strategies 
be investigated, because traditional methods may be in-
effective, further complicating the prevention and treat-
ment of PCa. 
The metabolic transformation in PCa cells results in an 
inability to accumulate citrate, which is reflected in dimin-Korean J Urol 2011;52:79-89
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FIG. 2. Summary of peripheral pros-
tate physiology in health (left) and 
disease (right). Healthy peripheral 
prostate physiology involves citrate 
accumulation via the zinc-dependent 
inhibition of m-aconitase, resulting in 
reduced ATP production via the Krebs 
cycle and a greater dependence on 
glucose and aspartate for ATP. In 
malignancy, peripheral prostate cells 
lose their ability to accumulate zinc, 
resulting in isomerization of citrate 
via m-aconitase for metabolism in the 
Krebs cycle and reduced citrate 
accumulation and production.
FIG. 3. Relationships between different quantification methods.
The relationships between different quantification methods are 
shown. The basic techniques of quantification are listed on the left
side, their relationships and combinations are shown in the mid-
dle of the diagram, and the result of these relationships is shown
on the right side. These are the principal methods of quantification
in prostate cancer (PCa) metabolomics. LC-MS: liquid chromatog-
raphy mass spectrometry, GC-MS: gas chromatography mass 
spectrometry, NMR: nuclear magnetic resonance, MRI: magnetic
resonance imaging, MRSI: magnetic resonance spectroscopic 
imaging, PET: positron emission tomography.
ished levels in prostatic fluid [35]. Furthermore, this may 
be exacerbated by tumor growth impeding the luminal 
space [29]. This process is summarized on the right side of 
Fig. 2. Increased cell proliferation requires increased mem-
braneogenesis and choline metabolites, reflected by in-
creased choline and creatine levels in the PZ in PCa [36]. 
Although citrate, choline, and creatine in prostate bio-
fluids and biopsies may be specific for prostate cancer, ap-
propriate clinical utilization of their relationships to ma-
lignant progression is currently limited.
METHODS OF QUANTIFICATION
Analysis of metabolites within the prostate and biofluids 
has been undertaken by use of a variety of techniques. For 
samples in solution, the most commonly used methods are 
nuclear magnetic resonance (NMR) spectroscopy or gas 
and liquid chromatography-mass spectrometry (GC-MS) 
and liquid chromatography-mass spectrometry (LC-MS). 
Other methods of analysis include high resolution magic 
angle spinning (HR-MAS) NMR and magnetic resonance 
spectrometry (MRS) in tissue/in vivo and imaging techni-
ques such as MRI or PET. Each of these methods helps to 
develop a snapshot of the metabolic state of the healthy or 
diseased prostate gland [37]. 
The basic principles of NMR spectroscopy applied in me-
tabolomics are that a short radiofrequency (RF) pulse is 
used to excite energy levels of the nuclear spin of the pro-
tons within the sample. Different protons within different 
metabolites resonate at different resonance frequencies 
causing individual signals and signal patterns that are spe-
cific for each metabolite. The signal intensity is directly 
proportional to the metabolite concentration, resulting in 
the capacity for simultaneous quantification of multiple 
metabolites [38]. Using the same principle, HR-MAS NMR 
allows for simultaneous quantification of metabolites in 
solid-state tissue samples. This specific application has 
been extensively applied in vitro to tissues, either from fine 
needle aspiration or biopsy or surgical excision. This appli-
cation is advantageous, because the analysis does not dis-Korean J Urol 2011;52:79-89
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TABLE 1. Analytical quantification methods for metabolites
Method Use Advantages Disadvantages Reference
NMR spectrometry
Proton solution NMR 
(also known as 
1H-NMR)
Analyses high energy and 
phospholipid metabolism to 
quantify amino acids, 
carbohydrates, fatty acids, lipids 
and phospholipids.
- Non-invasive
- Solution
- High precision 
- High temporal 
resolution
- Low per-experiment 
cost
- Minimal sample 
preparation required 
- Average analytical time 
of ten minutes
- Non-destructive
- Quantitative
- Less sensitive than mass 
spectrometry
[28,94]
31P-NMR Quantifies high energy phosphates 
(e.g. ATP, phosphocreatine), 
phospholipid precursors and 
sugar phosphates.
13C-NMR Quantifies metabolic fluxes of 
13C-labelled precursors (e.g. 
13C-labelled glucose fluxes 
through glycolysis), the TCA 
cycle, the pentose-phosphate 
cycle and de novo fatty acid 
synthesis
HR-MAS 
1H-NMR In vitro tissue applications [28,37,62,95]
Mass spectrometry (MS)
LC-MS Full spectrum analysis of solutions 
with multiple metabolites
- High sensitivity and 
specificity
- Full spectrum analysis
- Current gold standard 
for analyzing solutions
- Derivatization/chemical 
modification needed
- Destructive to sample
- Not fully quantitative 
without appropriate 
standards
[38]
GC-MS
PET
18F-fluorodeoxyglucose 
(
18F-FDG)
Accumulation in cancerous cells 
with upregulated, aerobic 
glycolysis
- Non-invasive 
- High precision
- High temporal 
resolution
- Current in vivo use and 
availability
- Low uptake by PCa 
tissue
- Uptake from other 
tissues resulting in 
background signals
[5,96]
18F-labeled amino acids Increased transport in tumors Currently not suitable for 
clinical detection of PCa
[5,96]
18F-fluorothymidine Reflects tumor cell proliferation 
and upregulated DNA 
metabolism
[5,96]
11C-labeled choline Upregulation of choline kinase in 
cancerous cells
[5,96]
Different analytical methods used in metabolomics have their own advantages and disadvantages that predispose them for different
applications as summarized in this table. NMR: nuclear magnetic resonance, LC-MS: liquid chromatography mass spectrometry, 
GC-MS: gas chromatography mass spectrometry, FDG: fluorodeoxyglucose, PCa: prostate cancer
tort the tissue architecture, such that further histopatho-
logical analysis is not jeopardized. 
Moreover, MRI when combined with NMR spectroscopy 
principles results in magnetic resonance spectroscopic 
imaging (MRSI), which allows for simultaneous quantifi-
cation of metabolites in a section being imaged, allowing 
for in vivo application. 
MS methods used with prostatic tissues and biofluids in-
clude LC-MS or GC-MS, which first separate metabolites 
in a sample by liquid or gas chromatography and then yield 
a mass spectrum of the resulting fractions [27]. MS meth-
ods have higher sensitivity than NMR methods but require 
more extensive sample preparation and can show chemical 
bias due to derivatization procedures. These methods have 
recently shown promise in PCa detection following urine 
analysis [22]. 
PET in combination with computerized tomography 
(CT) is widely used worldwide to produce three-dimen-Korean J Urol 2011;52:79-89
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TABLE 2. Summary of metabolites identified in vitro and status in PCa
Metabolite Context  Status in PCa Sample Reference
Citrate Normally high levels in 
prostate tissue and 
prostatic fluid
↓  - metastasis＜PCa＜BPH＜ 
healthy
Prostatic fluid [18,41-44]
↓  - metastasis＜PCa＜BPH＜ 
healthy
Prostate tissue [47,55,57,95]
Choline-containing 
compounds
Pre-cursors and products of 
membrane phospholipids
↑  - metastasis＞PCa＞BPH＞ 
healthy
Prostate tissue [19,55,57,61,79]
Spermine Proposed endogenous 
inhibitor to PCa growth
↓  - metastasis＜PCa＜healthy Prostatic fluid [18,41]
↓  - metastasis＜PCa＜healthy Prostate tissue [80,95]
Myo-inositol Osmoregulation ↓ Prostatic fluid [18,41]
↑ Prostate tissue [57,81]
Lactate Increased glycolysis 
(Warburg effect)
↑  - PCa＞BPH＞healthy Prostate tissue [19,52,55]
Alanine Increased glycolysis 
(Warburg effect)
↑  - PCa＞BPH＞healthy Prostate tissue [19,52,55]
Omega-6 fatty acids Promote PCa development ↑ Prostate tissue [54]
Sarcosine Activation of prostate cancer 
cells
↑  - correlated with invasiveness Urine and prostate 
tissue 
[22]
Choline＋creatine/ 
citrate
Metabolite ratio ↑  - PCa＞BPH＞healthy - significant 
correlation with Gleason score
Prostate tissue [51,97]
Citrate/spermine ↓ Prostatic fluid [41]
↓ Prostate tissue [97]
Total choline/citrate ↑  - PCa＞BPH＞healthy - significant 
correlation with Gleason score
Prostate tissue [51]
Choline/creatine ↑  - PCa＞BPH＞  healthy - significant 
correlation with Gleason score
Prostate tissue [51]
Citrate/creatine ↓  - significant correlation with 
Gleason score
Prostate tissue [51]
The table shows a summary of potential biomarkers for PCa identified in vitro by metabolomic methods, their context, status in PCa,
and the type of sample used. PCa: prostate cancer, BPH: benign prostatic hyperplasia
sional images of visceral structures that are otherwise dif-
ficult to visualize. A positron-emitting radiolabeled tracer 
is introduced into the body and circulates while attached 
to an endogenous, biologically active molecule. Neoplastic 
cells preferentially metabolize the tracer, resulting in an 
accumulation and increased emission of ionizing radiation 
in malignant tissue. When applying PET to PCa metab-
olomics, different tracers are used to utilize varied alter-
ations in cellular metabolic pathways to discriminate be-
tween healthy and malignant prostate tissue. 
These variations in approach to metabolomics are illus-
trated in Fig. 3 and are summarized in Table 1.
SINGLE METABOLITES AS BIOMARKER 
CANDIDATES IN PCa
In the context of prostate physiology and quantification 
methods, metabolomic analysis has seen the identification 
of several promising metabolites for quantifying disease. 
The utility of selected metabolites and metabolite ratios 
identified to date for PCa diagnostics and prognostics is 
summarized in Table 2.
It is well known that, compared with healthy prostate, 
BPH tissue, and prostate-specific biofluids, PCa is charac-
terized by low levels of citrate and polyamines (e.g., 
Spermine, myo-inositol), but high lactate, choline, and cre-
atine levels [18,37,39-41]. PCa leads to altered zinc metab-
olism, resulting in diminished zinc, and consequently cit-
rate, levels both in prostate tissue and in prostatic fluid [18, 
29,41-44]. Although citrate levels vary between PCa, BPH, 
and healthy PZ tissue, zinc levels remain relatively con-
stant between samples from healthy, BPH, and prostatitis 
tissues, but are markedly reduced in PCa by up to more 
than 90% [45]. Moreover, levels of citrate and zinc in pro-Korean J Urol 2011;52:79-89
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static tissue and fluid are identical, indicating that pro-
static fluid is representative of the metabolic status of the 
PZ. Such alterations to citrate and zinc levels imply that 
metabolic changes are essential to manifest malignant ac-
tivities in neoplastic cells. Thus, it is understood that re-
duced citrate and zinc occur early in the malignant trans-
formation to PCa [46]. This has been shown in vitro, as de-
creases in citrate exceed the volume of histopathologically 
identified cells, with the gap being the result of histologi-
cally unremarkable premalignant cells. However, these 
noncancerous cells contain genetic and metabolic alter-
ations without changes in histological architecture, which 
is known as the ‘field effect’ in cancer biology [29]. On the 
other side of the cancer spectrum, both zinc and citrate are 
undetectable in poorly differentiated PCa tumors [47], in-
dicating that the depletion of citrate and zinc is a pro-
gressive process.
Citrate is further reduced due to its use in increased 
membraneogenesis from malignant cell proliferation [29]. 
In addition, this process causes an increased requirement 
for choline and altered choline metabolism, the combina-
tion of which increases the concentration of choline-con-
taining metabolites [41,48]. In this context, radiolabeled 
ethanolamine, a choline metabolite, has been implicated 
as a possible marker [49,50]. Lactate and alanine levels are 
attributed to the Warburg effect [25], as well as to tissue 
hypoxia during the sampling process, and as a ratio are pro-
portional to tumor aggression and metastasis [51]. This is 
thought to be the result of PCa progression, but lactate has 
also been implicated in promoting metastasis via activa-
tion of molecular hypoxia-driven pathways, and upregula-
tion of specific growth factors and proangiogenic genes pro-
moting neovascularization, such as vascular endothelial 
growth factor (VEGF) [52,53]. The multifactorial nature of 
cancer has also been considered, with the influence of diet-
ary factors such as polyunsaturated fatty acids (PUFA), 
having been investigated. It has been shown that omega-6 
PUFA accumulate in malignant tissue samples but are un-
detectable in nonmalignant samples. Although this does 
render PUFA as an eligible biomarker, a lack of accumu-
lation in the peri-tumor margins suggests that the accumu-
lation is due to tumor growth and not to premalignant 
stages of cancer [54]. Choline, citrate, and spermine levels 
have been shown to correlate with Gleason score [18,44,55, 
56], whereas polyamine and sarcosine levels indicate PCa 
progression and tumor aggression [22,57]. Furthermore, 
sarcosine detected in the urine, via LC-MS/GC-MS, has 
been proposed as a method for detecting PCa and partic-
ularly the presence of metastases [22]. PCa progression to 
metastasis, as suggested by malignant metabolic changes 
shown on PET CT using 
11C-choline, have been confirmed 
histologically in lymph nodes after radical prostatectomy 
and external beam radiotherapy [58]. The ratio of choline 
to creatine over citrate (CC/Ci) is also effective in evaluat-
ing clinical in vivo MRSI results [59,60].
Although single metabolites [52,55,61] and metabolite 
ratios [51] have been shown to distinguish between malig-
nant and benign samples, they have been reported to lack 
sensitivity. Hence, the current consensus is that entire 
metabolic profiles are more sensitive in identifying and 
characterizing PCa [19,37,62]. This has been shown in PCa 
by using HR-MAS NMR to successfully identify areas of 
malignancy in prostate tissue [20,37,59,62]. When entire 
metabolomic profiles are evaluated by use of principal com-
ponent analysis, differentiation of cancerous and histologi-
cally benign prostate tissue samples has been shown to be 
highly significant (p＜0.0001) with an overall accuracy ＞
98%. Moreover, some principal components had sig-
nificant predictive powers in distinguishing between con-
fined (T2) and invasive (T3) PCa [62]. Metabolomic profil-
ing has also been shown to have an accuracy of 78% in pre-
dicting biochemical recurrence, which makes prognosis 
more individualized [63].
IN VITRO METABOLOMIC ANALYSIS OF 
BIOFLUIDS
The contents of biofluids, when analyzed for various cyto-
logical and biochemical abnormalities, reflect homeostasis 
at a given moment. In the context of PCa detection, appli-
cable biofluids include urine; blood; expressed prostatic se-
cretion (EPS), which is collected in an immediately sub-
sequent void of urine; and ejaculate. The possible preferred 
use of biofluids over biopsies, the current gold standard, is 
based on the less-invasive nature of sampling and that it 
can be undertaken frequently with only minimal risks of 
infection, bleeding, or discomfort. Although clinical use of 
1H-NMR on EPS was initially limited by low-volume sam-
ple size, recent research has developed methods to make 
this method more effective, with the use of smaller probes 
to improve analysis [38].
Current markers in prostatic fluid, including EPS and 
ejaculate, relate to previous in vitro research. Diminished 
citrate and zinc levels in prostatic fluid have been shown 
to be representative of prostate tissue status in various dis-
ease states [18,29,42-45]. This is supported by the correla-
tion of citrate and spermine depletion in prostatic fluid 
with Gleason score and citrate as an improvement on PSA 
in PCa detection [28,44].
However, false-positive results may occur with prostati-
tis-induced low citrate levels [64]. Zinc levels may be the 
differentiating factor, but further validation in prostatitis 
is required, given the various forms of this condition that 
may contribute to the inconclusive evidence [45,64]. In ad-
dition, false-positive results may be the consequence of 
pre-malignant transformation, which can only be deter-
mined subsequently when histology is the yardstick that 
is often normal in premalignant transformation, notwith-
standing the relationships of high-grade prostatic intra-
epithelial neoplasia (HGPIN) and atypical findings to ma-
lignant transformation in a proportion of “at risk” patients 
[29]. Citrate production has also been shown to cease after 
radiotherapy and androgen deprivation therapy [65,66], 
indicating the need for a thorough history as well as further Korean J Urol 2011;52:79-89
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TABLE 3. Summary of metabolites identified in vivo and status in PCa
Metabolite Status in PCa Method of analysis Reference
Citrate ↓  - metastasis＜PCa＜BPH＜healthy
1H-MRSI [32,97,98]
Choline ↑
1H-MRSI [35,99,100]
Lactate ↑  - PCa＞healthy＞BPH
1H-MRSI, 
13C-MRSI
Choline＋creatine/citrate ↑  - metastasis＞PCa＞BPH＞healthy
1H-MRSI, JPRESS (endorectal 
coil)
[60,97]
Citrate:choline ↓  - PCa＜BPH＜healthy
1H-MRSI [98]
Choline＋creatine/spermine ↑  - correlates with Gleason score JPRESS (endorectal coil)
Choline/creatine ↑  - PCa＞BPH (sensitivity 98.6% specificity 
85.7% in differentiating between PCa and 
BPH)
1H-MRSI
The table shows a summary of potential biomarkers for PCa identified in vivo by metabolomic methods, their status in PCa, and the
analytical method used. PCa: prostate cancer, BPH: benign prostatic hyperplasia
markers to assess response to treatment. False-negative 
results may occur with BPH-induced high levels of citrate 
and zinc, BPH being a common accompaniment of PCa. 
This scenario is less likely for the majority of PCa, however, 
because prostatic fluid findings mostly reflect the status of 
the PZ [29]. However, transitional zone cancers may be 
omitted from detection by using prostatic fluid, so further 
markers may be required for tumors arising in this part of 
the prostate. 
IN VIVO METABOLOMIC ANALYSIS OF PCa
The application of standard physiology, global metab-
olomic profiling, and identification of individual key me-
tabolites is currently being investigated to develop an accu-
rate, noninvasive, in vivo metabolomic analysis method to 
detect early PCa. Many different methods and approaches 
have been studied, some of which are summarized in Table 
3.
  In vivo, MRSI is currently the most widely used method 
of differentiating between healthy and malignant tissue by 
simultaneously imaging tissue structures and quantifica-
tion of metabolites in situ [67,68]. Although rectal coils 
were used previously, most in vivo MRI is now “whole 
body.” Similar to research in vitro, analysis was initially 
targeted at citrate and choline levels, which appeared to be 
promising [69]. As with prostatic fluid, analysis by MRSI 
of citrate and spermine depletion and choline elevation in 
prostatic tissue has been reported to correlate well with 
Gleason score [28,70,71]. However, this correlation is in-
consistent and has been attributed to vagaries of sampling 
with biopsy needles (e.g., small foci of tumors, tissue heter-
ogeneity, and Gleason score interpretation) [51], indicat-
ing a need for further and more comprehensive investiga-
tions. Citrate has also been stated to predict treatment re-
sponsiveness and relapse rates [27]. In addition, citrate 
quantification via MRSI has been reported to be superior 
to anatomic MRI in determining extracapsular extension 
and in reducing interobserver variability [72,73]. Further-
more, MRSI metabolomics can assist with prostate tissue 
sampling, being able to highlight areas of interest with a 
stated accuracy of over 90% [62]. 
Recent developments in PET for in vivo metabolomics 
use increased choline metabolism to visualize malignant 
cells with enhanced sensitivity. The radioactive PET 
marker 
11C-choline is known to be metabolized in ag-
gressive PCa and has been used to assist in visualizing bone 
metastases [74], as well as for the localization and staging 
of PCa [30]. This method of PET has been reported to ex-
hibit an accuracy rate of 73% in patients with PSA levels 
higher than 3 ng/ml [75]. The 
18F-labelled choline analogue 
has also been successful in detecting and staging PCa 
[30,76], whereas 
11C-leucine and 
14C-valine have been 
shown to be metabolized by PCa cells [77,78]. A more ex-
tensive review of choline-containing compounds as bio-
markers is available from Glunde and Serkova [40].
However, in vivo MRI and PET are not without their 
limitations. MRI was initially limited in spectral reso-
lution and was unable to measure individual metabolites. 
These limitations have been addressed recently, with the 
addition of diffusion-weighted imaging and dynamic con-
trast enhancement currently being trialled [19]. In addi-
tion, previous volume requirements for analysis have been 
addressed, with implementation of point-resolved spectro-
scopy (PRESS), which permits the analysis of smaller vol-
umes (1 μl) [28]. 
PET limitations pertain predominantly to the markers 
used and the rates at which these accumulate in targeted 
tissues. Ongoing research is being undertaken to find bet-
ter markers for accurate localization and staging of PCa.
VALIDATION OF PUTATIVE BIOMARKERS
Despite the already highlighted clinical need and scientific 
promise, all biomarkers that are identified require ex-Korean J Urol 2011;52:79-89
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tensive validation before their potential can be realized in 
a clinical setting. An example is the recent debate about 
sarcosine, a putative biomarker for the early detection of 
PCa. In 2009, Sreekumar et al reported a study in which 
prostate tissue, serum, and post-digital rectal examination 
(DRE) urine were analyzed with LC-MS and GC-MS. They 
demonstrated sarcosine levels in tissue to be significantly 
correlated with prostate malignancy and metastatic 
potential. In addition, they showed that sarcosine can in-
duce malignant changes when introduced to a prostate epi-
thelial cell culture line [22]. Finally, they showed that sar-
cosine/alanine ratios in urinary sediment and sarco-
sine/creatinine ratios in urinary supernatants can dis-
criminate modestly between PCa-positive and PCa-neg-
ative biopsy patients [22]. This last result of sarcosine as 
a potentially promising urinary biomarker created initial 
excitement [79,80]. However, in July 2010, García-Segura 
et al analyzed sarcosine levels in post-DRE urine samples 
in biopsy-confirmed patients and in patients with no evi-
dence of malignancy by use of GC-MS [81]. They found that 
sarcosine normalized to creatinine had no association with 
tumor stage or grade and concluded that it was more benefi-
cial than total PSA but was significantly worse than per-
centage free PSA. Since this second study was published, 
considerable debate has compared both studies and dis-
cussed their validity, with particular scrutiny paid to the 
study types (exploratory proof-of-concept versus com-
parative), composition of study cohorts, assay techniques, 
and sample types (urine sediment vs. urine supernatant) 
[82-89]. Independent confirmation seems now established 
that sarcosine levels in urine supernatants are not well cor-
related with cancer status [89,90]. Serum sarcosine levels 
also do not seem to correlate [82]. However, Sreekumar et 
al did confirm in an independent set of urine sediments that 
sarcosine/alanine ratios in urine sediments are correlated 
with biopsy status [85]. Thus, it appears that sarcosine lev-
els in urine sediments and in tissue might be potential bio-
marker candidates, whereas levels in urinary super-
natants or serum are not. It is currently unclear why a dis-
crepancy exists between the results from urinary super-
natant and those from sediment. In addition, in a new 
study, Jentzmik et al analyzed sarcosine levels in prostate 
tissue and showed that whereas sarcosine levels are 7% 
higher in malignant than in nonmalignant tissue, there is 
no correlation with tumor stage or grade [91].
In our opinion, the debate, although currently un-
resolved, has the potential to advance the field consi-
derably. It highlights that in metabolomics close attention 
must be paid to the whole pipeline of study setup and de-
sign, sample analysis, metabolite normalization, data 
treatment, and statistical analysis, because a change in 
any of these parameters can contribute to different results 
even when based on the same raw data. In addition, it 
shows that although putative biomarkers may show prom-
ise in a laboratory, extensive investigation and trialling is 
required before these biomarker candidates will be suit-
able as an effective screening method for PCa. Interestin-
gly, it has been highlighted that standardization in analy-
sis and reporting of putative biomarkers needs to be estab-
lished [83], as this will reduce premature and unnecessary 
hype among both PCa patients and practicing clinicians.
CONCLUSIONS 
There is no doubt that the novel approach of metabolomic 
profiling of PCa for early detection and quantitative analy-
sis of histopathology is exciting. However, in practice, a 
comprehensive correlation between metabolite data and 
clinicopathological findings needs to be established. One 
limitation to further development is the imprecision of PCa 
diagnosis in patients. A proposed solution to improving 
clinical and histologic diagnosis involves computer-aided 
analysis (CAIA) of prostate pathology slides, which has 
been shown to be more reliable than interobserver or in-
tra-observer analysis [92].
Metabolomic analysis can detect precancerous changes, 
and the use of biofluids as noninvasive samples appears to 
be promising. In vivo methods in combination with CT and 
MRI that further substantiate evidence from biofluids will 
also provide visual guidance to improve our current diag-
nostic methods. In addition to indicating disease pro-
gression, metabolomics also has a potential role in the fu-
ture in monitoring responses to therapeutic implementa-
tions [27], for example, in heralding or verifying chemo-re-
sistance or radio-resistance [93], thus permitting a more 
rational integration of these forms of treatment with surgi-
cal interventions. Further to this, it is considered that the 
future for individualizing PCa diagnosis and treatment 
will involve a combination of metabonomics and genetic 
analyses to provide the most favorable treatment outcomes 
for individual patients.
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